PLUS1
0.7955
-0.0367 (-4.41%)
-0.0367 (-4.41%)
Upgrade to Real-Time
Regular Market
Low
0.6501
High
2.63
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| AzurRx BioPharma Inc | AZRX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -0.0367 | -4.41% | 0.7955 | 15:49:11 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.87 | 0.7801 | 0.8706 | 0.8322 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 0.7901 | 0.7954 | 0.0053 | - | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,971 | 1,477,359 | $ 0.8044477 | $ 1,188,458 | 4,181,977 | 0.6501 - 2.63 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 15:49:08 | 83 | $ 0.7955 | USD |
AzurRx BioPharma Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 59.29M | 74.44M | 73.60M | $ - | $ - | -1.15 | -0.80 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | 1.90% |
AzurRx BioPharma News
| Date | Time | Source | News Article |
|---|---|---|---|
| 4/15/2021 | 07:30 | GlobeNewswire Inc. | AzurRx BioPharma CEO Issues Letter to Shareholders |
| 4/09/2021 | 06:04 | Edgar (US Regulatory) | Notice of Effectiveness (effect) |
| 4/06/2021 | 16:16 | Edgar (US Regulatory) | Post-effective Amendment to Registration Statement (pos Am) |
| 4/06/2021 | 07:00 | GlobeNewswire Inc. | AzurRx BioPharma Initiates Phase 2 Clinical Trial of.. |
| 4/01/2021 | 08:01 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 3/31/2021 | 17:27 | Edgar (US Regulatory) | Annual Report (10-k) |
| 3/31/2021 | 17:11 | Seeking Alpha | AzurRx slides after MS1819 fails in mid-stage cystic.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AZRX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.96 | 0.96 | 0.7801 | 0.8778205 | 1,614,042 | -0.1645 | -17.14% |
| 1 Month | 0.96 | 1.0699 | 0.76 | 0.9022156 | 3,583,598 | -0.1645 | -17.14% |
| 3 Months | 1.98 | 1.99 | 0.76 | 1.28 | 4,141,972 | -1.18 | -59.82% |
| 6 Months | 0.705 | 2.63 | 0.6701 | 1.47 | 5,640,916 | 0.0905 | 12.84% |
| 1 Year | 0.7063 | 2.63 | 0.6501 | 1.44 | 2,883,013 | 0.0892 | 12.63% |
| 3 Years | 2.6508 | 3.75 | 0.370868 | 1.42 | 1,100,863 | -1.86 | -69.99% |
| 5 Years | 5.06 | 5.60 | 0.370868 | 1.46 | 738,526 | -4.26 | -84.28% |
AzurRx BioPharma Description
| AzurRx BioPharma Inc is a development stage biopharmaceutical company. The company is focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome-related conditions. Its lead product candidate is MS1819, a yeast-derived recombinant lipase for exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF) and chronic pancreatitis (CP). |
